Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Talking to a pharmacist about your COPD inhalers might keep you out of the hospital

NCT ID NCT03704545

Disease control Sponsor: Centre Hospitalier Universitaire de Nīmes Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study tested whether having a pharmacist teach people with COPD about their medications could reduce sudden worsening of symptoms. 174 adults with moderate to severe COPD were given a 20-minute education session either at the hospital or at their local pharmacy, plus a 10-minute follow-up. The main goal was to see if this counseling lowered the number of flare-ups (exacerbations) after they returned home.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
pharmaceutical consultation (education about COPD treatments and inhaler use)
What this could lead to
If it works, this could show that simple medication counseling helps people with COPD avoid serious flare-ups and stay healthier at home.
What could go wrong
This is a completed study with 174 participants, so results are available but may not apply to all COPD patients. The intervention is just education, not a new drug, so any benefit is likely modest.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

174 people

The number who actually took part.

Started

Jan 2019

Finished

Oct 2021

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * The patient has signed the consent form. * The patient is affiliated to a health insurance programme * The patient is at least 18 years old (≥). * The patient is admitted to complete hospitalization (for patients in the "Hospital and Control" groups). * The patient is diagnosed with stage 2 to 4 Chronic Obstructive Pulmonary Disease. The diagnosis as well as the stage of the disease are validated by a pulmonologist at the facility. * The patient has one or more inhaler devices to treat Chronic Obstructive Pulmonary Disease. * The patient returns to his / her home when discharged from hospital (for patients in the "Hospital and Control" groups). * The patient is available for a follow-up of 12 months. Exclusion Criteria: * The subject participates in another interventional study. * The subject is in an exclusion period determined by a previous study. * The patient is under safeguard of justice. * The subject refuses to sign the consent. * It is not possible to give the patient (or his/her trusted-person) informed information.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic obstructive pulmonary disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic obstructive pulmonary disease

Contacts and locations

Locations

  • Nimes University Hospital

    Nîmes, 30029, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.